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A
 
BSTRACT
 
Bronchial asthma is a chronic inflammatory disease
of the conducting airways. Current asthma treatment
guidelines recommend inhaled corticosteroids (ICS) as
the first-line maintenance therapy for mild to severe
persistent asthma, because ICS are the most effica-
cious anti-inflammatory medication. Despite treatment
with ICS, suppression of inflammation is often incom-
plete and blockade by ICS of cysteinyl leukotriene
(CysLT) and thromboxane (TX) A
 
2
 
 biosynthesis is
limited. The addition of a CysLT
 
1
 
 receptor antagonist
to an ICS represents a reasonable alternative thera-
peutic approach for the treatment of asthma patients
whose symptoms remain uncontrolled on ICS alone.
Indeed, CysLT
 
1
 
 receptor antagonists are demonstrated
both to have an additive effect to ICS therapy and
to allow the reduction of ICS dosage. Thromboxane
modifiers also have an additive effect with low- to
moderate-dose ICS. Although the long-term useful-
ness of add-on therapy of CysLT or TX modifiers
(
 
vs
 
 long-acting 
 
β
 
2
 
-adrenergic receptor agonists) to
ICS is unclear, these alternatives are worthy of further
consideration.
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I
 
NTRODUCTION
 
Bronchial asthma is a chronic inflammatory disease of
the conducting airways that is characterized by bronchial
hyperresponsiveness and a variable degree of broncho-
constriction. Current asthma treatment guidelines recom-
mend inhaled corticosteroids (ICS) as the first-line
maintenance therapy for mild to severe persistent
asthma, because ICS are the most effective anti-
inflammatory medications.
 
1,2
 
 Inhaled long-acting 
 
β
 
2
 
-
adrenergic receptor agonists (LABA) are recommended
as the first-choice add-on therapy to ICS. Adding a
cysteinyl leukotriene (CysLT) modifier is a second-line
option. The CysLT are important pro-inflammatory medi-
ators, which are involved in airway smooth muscle
contraction, inflammatory cell accumulation, vascular
leakage and mucus hypersecretion in the asthmatic
airway.
Several clinical trials have compared the clinical
efficacy and safety of ICS and CysLT modifiers for the
treatment of persistent asthma; these investigations have
demonstrated that low-dose ICS is clinically more effec-
tive as first-line maintenance therapy for patients with
persistent asthma, who are undertreated and remain
symptomatic while taking a short-acting 
 
β
 
2
 
-adrenergic
receptor agonist alone.
 
3,4
 
 However, even high doses of
ICS cannot always control completely patients with
moderate or severe asthma.
 
5
 
 Indeed, it has been
reported that combinations of anti-asthmatic drugs with
different pharmacological mechanisms of action confer
significant additive efficacy to therapy with ICS.
 
6,7
 
Although antileukotriene drugs are used worldwide,
the usefulness of these drugs in the treatment of asthma
remains to be defined more precisely.
 
8,9
 
 Furthermore,
both a thromboxane (TX) A
 
2
 
 synthase inhibitor and TXA
 
2
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receptor antagonists are available for the treatment of
asthma in Japan. In the present review, we address the
efficacy of CysLT or TXA
 
2
 
 inhibition in asthmatic patients
receiving ICS therapy.
 
E
 
FFECT
 
 
 
OF
 
 
 
CORTICOSTEROID
 
 
 
ON
 
 
 
EICOSANOID
 
 
 
PRODUCTION
 
 
 
IN
 
 
 
THE
 
 
 
LUNG
 
Although corticosteroids are potent anti-inflammatory
agents, their mechanism of action remains uncertain.
Some 
 
in vitro
 
 experiments have suggested that cortico-
steroids cause decreased arachidonic acid synthesis in
inflammatory cells, such as alveolar macrophages pre-
treated with steroid.
 
10–12
 
 However, 
 
in vivo
 
 data do not
consistently demonstrate the inhibition of arachidonate
synthesis with corticosteroid therapy.
 
13–16
 
Pavord 
 
et al
 
.
 
13
 
 measured CysLT concentrations of
induced sputum in healthy control subjects and asthmatic
patients. Sputum leukotriene (LT) C
 
4
 
/D
 
4
 
/E
 
4
 
 concentra-
tions of CysLT were significantly greater in asthmatic
patients taking either 
 
β
 
-adrenergic agonists alone or in
mild persistent asthmatics who were taking daily ICS
(mean daily dose of beclomethasone (BDP) or equivalent
= 1440 
 
µ
 
g). A similar increase in CysLT concentrations
was also observed within 48 h in subjects having an
acute, severe exacerbation of asthma (Fig. 1). These
results suggest that CysLT produced in asthmatic airways
are not inhibited by high-dose ICS. O’Shaughnessy
 
et al
 
.
 
14
 
 demonstrated that inhaled fluticasone propionate
(1000 
 
µ
 
g/day) administered over a 2 week period inhib-
ited both the early and late bronchoconstrictor response
to inhaled allergen, but did not prevent allergen-evoked
urinary LTE
 
4
 
 excretion. This also indicates that administra-
tion of high-dose ICS does not block antigen-induced
CysLT production in the airway.
In another investigation, the effect of oral prednisone
for 6–9 days on eicosanoid concentrations in broncho-
alveolar lavage (BAL) fluid was determined in 14 atopic
asthmatic volunteers at baseline and after allergen
instillation.
 
15
 
 Prednisone reduced symptoms and inhaler
use, but had no significant effect on eicosanoid concen-
trations in BAL fluid. Prednisone did not decrease the
concentration of urinary LTE
 
4
 
 at baseline or after allergen
challenge.
In addition to CysLT, airway TX synthesis is also
increased in the airways of severe asthmatic patients.
 
16
 
This increase in TX concentrations in BAL fluid persists in
severe asthmatic patients taking large doses of oral corti-
costeroids (> 35 mg/day prednisone), suggesting that it
is also unlikely that corticosteroids inhibit TX production
in the asthmatic airway.
Louis 
 
et al
 
.
 
17
 
 demonstrated that significant, residual
eosinophilic inflammation (as marked by increased eosi-
nophil cationic protein) persisted in patients with moder-
ate and severe asthma after treatment with either high
doses of ICS or oral corticosteroids. Thus, treatment with
high-dose oral corticosteroids does not fully resolve
eosinophilic inflammation in patients with persistent
asthma.
 
17
 
 Accordingly, current data suggest that corti-
costeroids have no significant inhibitory effect on
eicosanoid production in the airway and do not modulate
asthmatic inflammation caused by CysLT or TX.
 
A
 
DDITIVE
 
 
 
EFFECTS
 
 
 
OF
 
 C
 
YS
 
LT 
 
ANTAGONISTS
 
 
 
ON
 
 
ICS 
 
THERAPY
 
Although current guidelines recommend ICS as first-line
treatment for patients with persistent asthma,
 
18
 
 many
patients remain symptomatic despite ICS treatment.
Increasing the dose of ICS is one therapeutic option.
However, several lines of evidence also suggest the
possibilities of alternative strategies. Laviolette 
 
et al
 
.
 
19
 
examined the additive effect of montelukast, a CysLT
 
1
 
Fig. 1
 
Sputum cysteinyl leukotriene (CysLT) concentration in
healthy and asthmatic subjects. Subjects with asthma were sub-
divided into those with mild episodic asthma requiring treatment
with an inhaled 
 
β
 
2
 
-adrenergic receptor agonist (as needed) only
(
 
n
 
 = 10) and those with persistent asthma requiring regular
treatment with inhaled corticosteroids (
 
n
 
 = 10). Six subjects
receiving 30 mg prenisolone daily were studied within 48 h
of an exacerbation of asthma. Sputum leukotriene C
 
4
 
/D
 
4
 
/E
 
4
 
concentrations were significantly greater in subjects with asthma
than in normal controls. Reproduced with permission from
Pavrod 
 
et al
 
.
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receptor antagonist, to low-dose ICS therapy in asth-
matics, who were not controlled adequately with corti-
costeroid doses equivalent to 400–500 
 
µ
 
g BDP. They
demonstrated that montelukast provided additional
control of asthma and, although montelukast had only
approximately one-half of the bronchodilatory effect of
400 
 
µ
 
g BDP, the combination of these two medications
resulted in augmented improvement in forced expiratory
volume in 1 s (FEV
 
1
 
; Fig. 2). The addition of the CysLT
 
1
 
receptor antagonist zafirlukast to 
 
≥
 
 1200 
 
µ
 
g/day equiv-
alent dose of BDP further improved pulmonary function
and asthma symptoms and reduced the risk of asthma
exacerbations.
 
20
 
 These data suggest that asthma symp-
toms and exacerbations caused by CysLT may not
always be controlled adequately by high-dose ICS
alone.
Price 
 
et al
 
. compared the clinical benefits of adding
montelukast to budesonide against doubling the bude-
sonide dose for 12 weeks in adults with asthma
inadequately controlled by inhaled budesonide (800 
 
µ
 
g/
day).
 
21
 
 A faster onset of action was observed in the
montelukast group and both groups showed comparable
improvement over the 12 week therapeutic period. This
report suggests that the addition of montelukast to
inhaled budesonide can be an effective and well-
tolerated alternative to doubling the dose of inhaled
budesonide in adult asthma patients experiencing symp-
toms and inadequate control on budesonide alone.
The CysLT
 
1
 
 antagonists may also allow for a reduction
in dosage of ICS and/or oral corticosteroids. Patients with
severe asthma require daily medication with anti-
inflammatory agents, most commonly oral and high-dose
ICS. Although ICS are effective in the long-term treatment
of asthma, there are significant concerns for the long-
term use of these drugs, including impairment of growth
and development in children, the development of osteo-
porosis and the suppression of the hypothalamic–
pituitary–adrenal axis.
 
22–25
 
 Prior studies have shown that
adding a CysLT
 
1
 
 receptor antagonist to ICS in patients
with uncontrolled asthma improves asthma control.
 
19–21
 
The ICS-reducing capability of a CysLT
 
1
 
 receptor antago-
nist has been demonstrated in several independent inves-
tigations.
 
26–28
 
 Tohda and Fujimura 
 
et al
 
.
 
26
 
 demonstrated
that montelukast reduced the need for ICS while main-
taining asthma control over a 24 week period. After a
4 week run-in period, 191 moderate-to-severe asthmatic
patients whose asthma had been well controlled with
daily ICS therapy (BDP 800–1600 
 
µ
 
g/day) were ran-
domly assigned to one of two treatment groups (placebo
or montelukast) in a 24 week, multicentre, double-blind
study. After a 50% reduction in the ICS dose every
8 weeks, morning and evening peak expiratory flow rates
(PEFR) were maintained over the 24 week treatment
period in the montelukast group. These data suggest that
CysLT
 
1
 
 receptor antagonists may be useful for sustained
treatment in patients with asthma who require high doses
of ICS and that the dose of ICS may be decreased for
significant periods in these patients.
 
26
 
Although the mechanism of the additive effect of
leukotriene modifiers with ICS is unclear, it has been
reported that airway responsiveness to AMP and surro-
gate indices of inflammation, such as exhaled nitric oxide
and blood eosinophils, are attenuated by the addition of
montelukast.
 
29
L
 
ONG
 
-
 
ACTING
 
 
 
β
 
2
 
-
 
ADRENERGIC
 
 
 
RECEPTOR
 
 
 
AGONISTS VERSUS CYSLT
The addition of a LABA or CysLT1 receptor antagonist to
ICS has been recommended in asthmatic patients whose
symptoms remain uncontrolled on ICS.1,2 Prior studies
have shown that the addition of either a LABA or an
Fig. 2 Effect of the addition of montelukast or inhaled
corticosteroids on forced expiratory volume in 1 s (FEV1;
mean ± SEM) as a percentage change from baseline. Treatment
groups are as follows: (i) montelukast 10 mg + beclometha-
sone (BDP) 400 µg (montelukast + BDP group); (ii) placebo
+ BDP 400 µg (BDP group); (iii) montelukast + inhaled
placebo (montelukast group); and (iv) placebo + inhaled
placebo (placebo group). AM and PM removal, morning and
evening BDP inhaler, respectively, were replaced with a placebo
inhaler in the placebo and montelukast groups. The withdrawal
of BDP caused a decrease in FEV1, which was attenuated by
approximately half, in the montelukast group compared with the
placebo group. The addition of montelukast to BDP caused an
increase in FEV1, which exceeded the effect of BDP alone.
Reproduced with permission from Lavoilette et al.19
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antileukotriene is more effective at controlling asthma
symptoms than increasing the dose of corticosteroid
alone.30,31 Recently, a randomized, controlled trial has
been reported in which the efficacy of adding monte-
lukast versus ICS to salmeterol was compared.32 The
percentage of patients with asthma exacerbations was
used as the primary end-point and the results were
comparable in both groups. Asthma exacerbations
occurred in only 20.1% of patients receiving montelukast
+ fluticasone and 19.1% of patients treated with
salmeterol + fluticasone. Although salmeterol + flutica-
sone caused a greater increase in FEV1 and morning
PEFR than montelukast + fluticasone, asthma-specific
quality of life and nocturnal awakenings were similar
between the groups. The conclusion of this study was
that the addition of montelukast in patients whose
symptoms remained uncontrolled by inhaled fluticasone
could provide equivalent clinical control to salmeterol.
However, the current guidelines do not recommend this
alternative as the first-line therapy for moderate or
severe (level III or IV) asthmatics.1,2
Bronchodilatory effects have been used as a primary
end-point in clinical trials for examining the efficacy of
anti-asthmatic drugs. The LABA are bronchodilators and
do not have an anti-inflammatory effect, whereas CysLT
antagonists block CysLT-induced airway reactions, such
as bronchoconstriction, airway leakage and airway eosi-
nophilia Nonetheless, the bronchodilatory effect of LABA
in patients with asthma, as assessed as FEV1 and PEFR,
exceeds that of leukotriene modifiers.
ADDITIVE EFFECTS OF CYSLT ANTAGONISTS TO 
ICS IN PATIENTS WITH ASPIRIN-INDUCED 
ASTHMA
Asthma attacks caused by aspirin or other non-steroidal
anti-inflammatory drugs (NSAIDs) are the hallmark of
aspirin-induced asthma (AIA), which has been observed
in approximately 5–15% of adult asthmatic patients.33
Both exhaled CysLT and urinary excretion of LTE4 are
increased by two- to 10-fold in patients with AIA
compared with patients with aspirin-tolerant asthma
(ATA); this corresponds to clinical evidence of constitu-
tive, genetic overexpression of the LTC4 synthase.34,35
Aspirin challenge causes an increase in CysLT levels in
BAL fluid and urine34,36 and antileukotrienes prevent
aspirin-induced bronchoconstriction.37 These findings
suggest that CysLT has a critical role in AIA. Further-
more, antileukotrienes may be more effective in patients
with AIA compared with ATA. Dahlen et al. evaluated
the benefits of adding the CysLT1 receptor antagonist
montelukast to a group of patients with AIA and moder-
ate to severe asthma receiving conventional controller
therapy, including corticosteroids.38 The addition of
montelukast improved pulmonary function and the
control of asthma beyond that which was achieved by
conventional anti-asthmatic controller therapy. There
was a striking 54% decrease in the incidence of asthma
exacerbations. The baseline treatment included inhaled,
inhaled and oral or only oral corticosteroids in 90% of
patients receiving montelukast. Interestingly, the thera-
peutic response to montelukast included patients with
different baseline characteristics and did not correlate
with baseline urinary LTE4. Accordingly, the mechanism
for the superior efficacy of antileukotriene therapies in
AIA remains undefined.
ADDITIVE EFFECTS OF TXA2 ANTAGONISTS ON 
ICS THERAPY
It has been reported that the inhaled TX mimetic
U46619 is a potent bronchoconstrictor in normal and
asthmatic subjects and that sub-threshold concentrations
Fig. 3 Mean (± SEM) values for the percentage increases in
morning peak expiratory flow rate (PEFR) caused by treatment
with the thromboxane synthesis inhibitor ozagrel hydrochloride
() or placebo () in asthmatic patients undergoing beclometh-
asone inhalation therapy (800 µg/day) for 8 weeks or more.
*P < 0.01. Reproduced with permission from Fujimura et al.45
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of U46619 cause airway hyperresponsiveness to metha-
choline in asthmatic subjects.39 Thromboxane synthetase
inhibitors suppress bronchoconstriction caused by various
bronchoconstrictive agents40 and TXA2 has been impli-
cated in acute bronchoconstriction after allergen inhala-
tion in asthmatics.41,42 We have also reported that the
selective TX synthetase inhibitor ozagrel hydrochloride43
or the TX receptor antagonist seratrodast44 reduce
bronchial hyperresponsiveness in asthmatic patients.
Accordingly, TXA2 may be a significant mediator in the
pathophysiology of asthma. Both TXA2 synthase inhibi-
tors and TXA2 receptor antagonists are available for the
treatment of asthma in Japan.
Fujimura et al. examined the efficacy of the add-on
use of ozagrel hydrochloride, a TX synthetase inhibitor, to
ICS in 70 asthmatic patients uncontrolled on 800 µg/day
BDP (Fig. 3).45 Ozagrel hydrochloride had an additive
effect to ICS compared with placebo. An increase in
PEF was observed in approximately 30% of patients
receiving ozagrel hydrochloride. Fukuoka et al. have
shown that seratrodast, a TXA2 receptor antagonist,
improves PEFR and bronchial hyperresponsiveness in
asthmatic patients uncontrolled on 400 µg/day BDP.46
Seratrodast also reduced the concentration of eosinophil
cationic protein in sputum.46 These reports indicate that
TX inhibition improves clinical symptoms and airway
hyperresponsiveness by reducing airway inflammation
when added to low to moderate doses of ICS. There is
evidence suggesting that the ratio of urinary eicosanoids
may predict of the efficacy of TXA2 receptor antago-
nism.47 Where the ratio of urinary 11-dehydro-TXB2/LTE4
was high (18 of 45 subjects; 40%), there was a corre-
sponding decrease in the asthma symptom score after
treatment with seratrodast.
The additive efficacy of ICS and TX inhibition on eosi-
nophilic inflammation in asthmatic airways remains to
be fully elucidated. In one prior report, treatment with
seratrodast reduced: (i) the number of submucosal EG2+
eosinophils; and (ii) the numbers of cells expressing
monocyte chemotactic protein-3, RANTES, macrophage
inflammatory protein-1α and eotaxin in the submucosa
of asthmatic airways.48
We conclude that although corticosteroids (ICS or
oral) are the most efficacious anti-inflammatory agents
for the treatment of asthma, corticosteroids do not block
inflammatory responses elicited by CysLT or TX. Recent
investigations suggest that adding a CysLT or TX modifier
may be a useful therapeutic alternative for patients not
responding adequately to ICS.
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